Concepedia

Markus Hinder

MH

21

Publications

889

Citations

18

H-Index

1998

Active since

Affiliations

Novartis (Switzerland)(Current)

University of St.Gallen

University of Tübingen

University of Pennsylvania

Sanofi (United States)

Markus Hinder is an author at Novartis (Switzerland) specializing in medicine, pharmacology, and drug discovery.

ORCID

Top concepts

Publications per year

1998–2025

21

Publications

21

Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension

Tzung‐Dau Wang, Ru‐San Tan, Hae‐Young Lee et al. · Hypertension · 2016 · 134 citations

The effect of LCZ696 (sacubitril/valsartan) on amyloid‐β concentrations in cerebrospinal fluid in healthy subjects

Thomas Langenickel, Chiaki Tsubouchi, Surya Ayalasomayajula et al. · British Journal of Clinical Pharmacology · 2015 · 109 citations · Full text

Analysis of pharma R&D productivity – a new perspective needed

Alexander Schuhmacher, Markus Hinder, Alexander von Stegmann und Stein et al. · Drug Discovery Today · 2023 · 70 citations

, , +8

LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia

Daniel J. Rader, Eleftheria Maratos–Flier, A. Nguyen et al. · The Journal of Clinical Endocrinology & Metabolism · 2021 · 61 citations · Full text

The upside of being a digital pharma player

Alexander Schuhmacher, Alexander Gatto, Markus Hinder et al. · Drug Discovery Today · 2020 · 60 citations

, , +4

Rows per page

1–5 of 21